These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33485947)

  • 1. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
    Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
    Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC.
    Wang L; Zhi X; Zhu Y; Zhang Q; Wang W; Li Z; Tang J; Wang J; Wei S; Li B; Zhou J; Jiang J; Yang L; Xu H; Xu Z
    Oncotarget; 2015 Oct; 6(32):33805-22. PubMed ID: 26393880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
    Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
    Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.
    Zhang JJ; Zhu Y; Xie KL; Peng YP; Tao JQ; Tang J; Li Z; Xu ZK; Dai CC; Qian ZY; Jiang KR; Wu JL; Gao WT; Du Q; Miao Y
    Mol Cancer; 2014 May; 13():130. PubMed ID: 24884523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
    Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
    Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and
    Urey C; Hilmersson KS; Andersson B; Ansari D; Andersson R
    Anticancer Res; 2017 Nov; 37(11):6031-6039. PubMed ID: 29061782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
    Mimeault M; Johansson SL; Senapati S; Momi N; Chakraborty S; Batra SK
    Cancer Lett; 2010 Sep; 295(1):69-84. PubMed ID: 20303649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.
    Torres MP; Ponnusamy MP; Chakraborty S; Smith LM; Das S; Arafat HA; Batra SK
    Mol Cancer Ther; 2010 May; 9(5):1419-31. PubMed ID: 20423995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
    Bafna S; Kaur S; Momi N; Batra SK
    Br J Cancer; 2009 Oct; 101(7):1155-61. PubMed ID: 19738614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells.
    Fauquette V; Perrais M; Cerulis S; Jonckheere N; Ducourouble MP; Aubert JP; Pigny P; Van Seuningen I
    Biochem J; 2005 Feb; 386(Pt 1):35-45. PubMed ID: 15461591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling.
    Rajesh C; Sagar S; Rathinavel AK; Chemparathy DT; Peng XL; Yeh JJ; Hollingsworth MA; Radhakrishnan P
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.
    Lahdaoui F; Delpu Y; Vincent A; Renaud F; Messager M; Duchêne B; Leteurtre E; Mariette C; Torrisani J; Jonckheere N; Van Seuningen I
    Oncogene; 2015 Feb; 34(6):780-8. PubMed ID: 24608432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.